Capturing an Asteroid: How NASA Could Do It

NASA's bold plan to drag an asteroid into orbit around the moon may sound like science fiction, but it's achievable with current technology, experts say.

President Barack Obama's 2014 federal budget request, which will be unveiled today (April 10), likely includes about $100 million for NASA to jump-start an asteroid-capture mission, U.S. Senator Bill Nelson (D-FL) said last week.

The plan aims to place a roughly 23-foot-wide (7 meters) space rock into a stable lunar orbit, where astronauts could begin visiting it as soon as 2021 using NASA's Space Launch System rocket and Orion capsule, Nelson said.

While challenging, the mission is definitely doable, said Chris Lewicki, president and chief engineer of billionaire-backed asteroid-mining firm Planetary Resources. [NASA's Asteroid-Capture Plan (Video)]

"Return of a near-Earth asteroid of this size would require todays largest launch vehicles and todays most efficient propulsion systems in order to achieve the mission," Lewicki, who served as flight director for NASA's Spirit and Opportunity Mars rovers and surface mission manager for the agency's Phoenix Mars lander, wrote in a blog post Sunday (April 7).

"Even so, capturing and transporting a small asteroid should be a fairly straightforward affair," Lewicki added. "Mission cost and complexity are likely on par with missions like the [$2.5 billion] Curiosity Mars rover."

Spurring solar system exploration

NASA's idea is similar to one proposed last year by scientists based at Caltech's Keck Institute for Space Studies in Pasadena.

The Keck study estimated that a robotic spacecraft could drag a 23-foot near-Earth asteroid (NEA) which would likely weigh about 500 tons into a high lunar orbit for $2.6 billion. The returns on this initial investment are potentially huge, the researchers said.

"Experience gained via human expeditions to the small returned NEA would transfer directly to follow-on international expeditions beyond the Earth-moon system: to other near-Earth asteroids, [the Mars moons] Phobos and Deimos, Mars and potentially someday to the main asteroid belt," the Keck team wrote in a feasibility study of their plan.

See more here:

Capturing an Asteroid: How NASA Could Do It

Inside NASA's Plan to Catch an Asteroid (Bruce Willis Not Required)

NASA's newly unveiled asteroid-capture plan is still in its early stages, but some details are already emerging about how the audacious mission might work.

President Barack Obama's 2014 federal budget request, which was released Wednesday (April 10), gives NASA $105 million to jump-start a program that would snag an asteroid and park it near the moon. Astronauts would then visit the space rock using the agency's Space Launch System rocket and Orion capsule, perhaps as early as 2021.

"This mission represents an unprecedented technological feat that will lead to new scientific discoveries and technological capabilities and help protect our home planet," NASA chief Charles Bolden said in a statement. [NASA's Asteroid-Capture Mission: How It Works (Images)]

The space agency is still working out how exactly to pull off the mission, which officials are calling the "Asteroid Initiative" or "Asteroid Retrieval and Utilization Mission" at the moment. But a few things are already clear.

For starters, the probe that will chase down and capture the 25-foot (8 meters) or so asteroid will be unmanned. And it will be powered by solar electric propulsion, which generates thrust by accelerating charged particles called ions.

Ion thrusters have been used on other NASA probes, including Dawn, which recently spent a year orbiting the huge asteroid Vesta before departing for the dwarf planet Ceres. But engineers will need to develop an advanced version for the Asteroid Initiative craft, since it will be towing a 500-ton space rock over millions of miles.

"This mission accelerates our technology development activities in high-powered solar electric propulsion," Michael Gazarik, NASA Associate Administrator for Space Technology, said in a statement.

Still, it may take several years for the probe to meet up with the asteroid. The spacecraft will then envelop the space rock with a bag of sorts, as a newvideo animation of NASA's Asteroid Initiative missiondepicts, and de-spin the rock, likely using thrusters.

The asteroid will then be towed to a "stable orbit in the Earth-moon system where astronauts can visit and explore it," NASA officials wrote in a mission description Wednesday.

These visits will be made possible by Orion and the Space Launch System, which are slated to begin flying crews together by 2021. The NASA animation shows astronauts aboard Orion meeting up with the space rock, which the retrieval probe is still holding onto.

See original here:

Inside NASA's Plan to Catch an Asteroid (Bruce Willis Not Required)

Traditional Indian systems of medicine to be promoted abroad

New Delhi, April 10 (IANS) As part of an initiative to promote traditional Indian systems of medicine abroad, the health ministry has signed agreements and set up research facilities to collaborate with international universities, an official said.

The department of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) has been making efforts to promote Indian systems of medicine abroad, a health ministry official said Wednesday.

Among initiatives taken is the setting up of the Centre for Research in Indian System of Medicine (CRISM) under the National Centre for Natural Products Research (NCNPR), University of Mississippi, US, to facilitate collaborative research and disseminate information on Ayurveda, Siddha and Unani medicines.

The department also signed a Memorandum of Understanding (MoU) with the Institute for Social Medicine, Epidemiology and Health Economics, Charite University, Berlin (Germany), to conduct a collaborative research on effectiveness and safety of Ayurveda as a treatment system.

An Indo-US interactive meet was organised on AYUSH research to explore the feasibility to conduct joint Indo-US Ayurveda research and to facilitate Ayurveda's entry into mainstream US medicine, the official added.

Apart from this, the health minister of Malaysia visited the AYUSH department and discussed various issues pertaining to cooperation on traditional systems of medicine, the official said.

Go here to read the rest:

Traditional Indian systems of medicine to be promoted abroad

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha …

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to

http://www.reportlinker.com/p01158259/European-Nuclear-Medicine-/-Radiopharmaceuticals-Market-%5BSPECT/PET-Radioisotopes-Technetium-F-18%5D-%5BBeta/Alpha-Radiation-Therapy-I131-Y-90%5D-%5BApplications-Cancer/Oncology-Cardiac%5D--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017]

The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are only 5 major reactors in the world and most of the countries are completely dependent on the productions from those reactors. A few countries such as Poland, Australia, Argentina, and South Africa have started producing Tc-99m at their own reactors in a small scale. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Scope of the Report

Link:

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha ...

Bristol-Myers Squibb Foundation, Morehouse School of Medicine Partner to Spread Lessons from Together on Diabetesâ„¢ …

PRINCETON, N.J.--(BUSINESS WIRE)--

The Bristol-Myers Squibb Foundation and Morehouse School of Medicine (MSM) today jointly announced the creation of the Morehouse School of Medicine/Bristol-Myers Squibb Foundation Partnership for Equity in Diabetes. The partnership will be based at MSMs National Center for Primary Care (NCPC) in Atlanta.

The partnership, which is funded through a five-year, $2.1 million grant from the Foundation, will share successful models and best practices emerging from the Foundations Together on Diabetes initiative and other demonstration projects with the broader U.S. diabetes, community health, public health and primary care practice communities. To date, Together on Diabetes has provided $44.4 million in funding to grantees that are developing, implementing and evaluating community-based care and support projects in and with more than 55 heavily affected communities across the U.S.

Given the devastating impact of diabetes on minorities, the elderly and the poor, there is great urgency to both figure out what works and to share and scale those solutions, said John L. Damonti, president, Bristol-Myers Squibb Foundation. We are fortunate to partner in this work with Morehouse School of Medicine, which is a constant and transformative force in creating health equity in the United States.

Through this grant and the formation of the Partnership for Equity in Diabetes, we have a strategic opportunity to celebrate what is really working in diverse communities across the country, to share their lessons learned and to engage new communities in working together to achieve more optimal diabetes health outcomes for all, said George Rust, Professor of Family Medicine and Director, NCPC, Morehouse School of Medicine.

Announcement of the partnership comes during National Minority Health Month, which is a call to action and unity in the effort to reduce health disparities. Type 2 diabetes is a serious public health problem in the U.S. that places a disproportionately higher disease burden on minority populations. Approximately 18.7 percent of African Americans and 11.8 percent of Hispanic/Latino Americans over age 20 live with the disease compared with 8.3 percent of the total U.S. population. Compounding these statistics, minority populations also face disparities in access to services and supports needed for successful and sustained control of their diabetes.

The Bristol-Myers Squibb Foundation launched Together on Diabetes in the United States in November 2010. The five-year, $100 million U.S. arm of the initiative targets adult populations disproportionately affected by type 2 diabetes and focuses on improving their health outcomes by strengthening patient self-management education, cultivating community-based supportive services and promoting broad-based community mobilization.

NCPC is the only congressionally sanctioned academic research, training and resource center focused on promoting excellence in community-oriented primary care and optimal health outcomes for all Americans, with a special focus on serving underserved communities.

Through this partnership, NCPC will capture, spread and replicate successes drawn from Together on Diabetes grantees and other demonstration and quality improvement projects through three core activities:

You can learn more about Together on Diabetes at http://www.TogetherOnDiabetes.com. To view an interactive map showing the location and project details of the Together on Diabetes project sites in the U.S., go to http://www.bms.com/togetherondiabetes/partners/Pages/partners-map.aspx.

More:

Bristol-Myers Squibb Foundation, Morehouse School of Medicine Partner to Spread Lessons from Together on Diabetesâ„¢ ...

North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion by 2017

DALLAS, April 10, 2013 /PRNewswire/ --

The"North American Nuclear Medicine/Radiopharmaceuticals Market& Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13)-Forecast to 2017"analyzes and studies the major market drivers, restraints, and opportunities in North America, Latin America, Europe, Asia, and Rest of the World.

Browse

http://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html

Early buyers will receive 10% customization on this report.

This report studies the North American nuclear medicine market over the forecast period 2012-2017.

The North American radiopharmaceutical market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%. It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 15% in mature markets such as North America, between 2010 and 2030, however shortage of Mo-99/Tc-99m has been a threat to this industry. The scheduled shutdown of the NRU reactor in 2016 is a major risk for manufacturers in the near future. Companies have increased the production of thallium to meet the shortage, as it is the most commonly used substitute for technetium-99 in cardiac-stress tests, conducted to evaluate the functioning of coronary arteries. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and other factors such as rising awareness of radiopharmaceuticals among physicians, alpha radio immunotherapy based targeted cancer treatment, and ready availability of north american nuclear medicine / radiopharmaceutical market from cyclotrons have driven the market. High cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals are major hurdles to growth of the market.

North America is the dominant market for diagnostic radioisotopes. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m.

Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.), Cardinal Health dominated with more than 40% share in 2012.

View post:

North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion by 2017

BG Medicine Welcomes CE Mark for Galectin-3 Test

WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, welcomed the announcement today that Abbott has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT immunochemistry platform.

The launch of the ARCHITECT Galectin-3 test under CE Mark will further expand the availability of galectin-3 testing in several European countries, pending country registration. BG Medicine is partnering with four diagnostic instrument manufacturers to commercialize automated versions of the BGM Galectin-3 test.

"The launch of the ARCHITECT Galectin-3 test under CE Mark is another important step in our commercial strategy. We are very pleased with the progress made by our partner Abbott, a worldwide leader in in vitro diagnostics, to expand the use of galectin-3 testing in heart failure patients," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. The announcement will strengthen our ability to drive the growth of galectin-3 testing throughout the world."

"Galectin-3 is a powerful indicator of prognosis and risk for readmission in heart failure. Having a rapid turn-around galectin-3 result means heart failure patients at high-risk for such adverse events can be more readily identified," said Stefan Anker MD, PhD and President of the Heart Failure Association of the European Society of Cardiology. "Given the rise in heart failure, it is critical we introduce new tools that aid fast clinical decision making processes and provide options to explore new interventions."

In addition to Abbott, BG Medicine is partnering with Alere Inc., bioMerieux SA, and Siemens Healthcare Diagnostics Inc. to supply automated versions of its galectin-3 test to key segments of the market. Earlier this year, bioMerieux SA launched the test in Europe and in certain other territories that recognize the CE Mark.

About Galectin-3 testing

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day readmission.

About BG Medicine, Inc.

BG Medicine, Inc. (BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3(R) test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE(TM) test for the risk prediction of major cardiovascular events is expected to be launched in Europe in the first half of 2013. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

View original post here:

BG Medicine Welcomes CE Mark for Galectin-3 Test

Medical School At Mt. Sinai Pays More Attention To Humanities

To view our videos, you need to enable JavaScript. Learn how. install Adobe Flash 9 or above. Install now. Then come back here and refresh the page.

Ronnie Tisdale joined a South Asian a capella group during his undergraduate studies. It was an extracurricular activity he was able to enjoy only after he was granted early acceptance into Mount Sinai's Icahn School of Medicine.

"I was really able to explore and really appreciate the beauty of a college education, to be able to take foreign languages, to study music," he says.

Tisdale is part of Mt. Sinai's Humanities and Medicine program, which allows students to forego traditional pre-med requirements like organic chemistry, physics and even the MCAT exam.

Now the school is expanding the 25-year old program, recruiting from different undergraduate disciples to eventually make up half of its class. Dean David Muller says they want to free students from the culture of aggressive competition and outdated requirements, which may sap creativity.

"They've done as well as their peers," Muller says. "This program will provide a very different approach for people who are creative and can sustain, nurture their creativity throughout college and bring that to medical school and help us change medical school, help us change the practice of medicine."

Mt. Sinai hopes the now Flex-Med program will also attract less privileged students and those disadvantaged due to systematic inequalities.

"We dont have enough students of color in medical schools. We don't have enough students who are from the LGBT community," Muller says. "It clearly translates into worse care for people who come from groups that are underrepresented in medicine."

Recently, Tisdale saw this in action while shadowing doctors at Elmhurst Hospital. He was able to assist a Lebanese patient, because he now speaks Arabic.

"Whether it's knowing someone's language, knowing a little bit more about someone's culture, that enhances the doctor patient relationship," Muller says.

Go here to read the rest:

Medical School At Mt. Sinai Pays More Attention To Humanities

University at Buffalo Unveils HOK Design for Downtown Medical School

State-of-the-art medical school and integrated transit station will anchor vibrant mixed-use district.

Buffalo and New York, NY (PRWEB) April 10, 2013

The seven-story medical school will bring 2,000 UB faculty, staff and students daily to downtown Buffalo and, at more than 500,000-square-feet, will be one of the largest buildings constructed in Buffalo in decades. HOKs design features two L-shaped structures linked to create a six-story, light-filled glass atrium that includes connecting bridges and a stairway. Serving as the buildings main interior avenue, the atrium will be naturally illuminated by skylights and two glass walls, one along Washington Street and one at the terminus of Allen Street.

The building, which HOK is designing for LEED Gold certification, will have a facade clad with a high-performance terra-cotta rain-screen and a glass curtain wall system that brings daylight deep inside.

Incorporating the NFTA Allen Street transit hub into the medical schools ground floor provides convenient mass transit access, furthering the development of a sustainable, vibrant community.

The new medical school will help the university achieve objectives critical to the UB 2020 strategic plan: creation of a world-class medical school, recruitment of outstanding faculty-physicians to the university and transformation of the region into a major destination for innovative medical care and research.

The new design allows us to grow our class size from 140 to 180, educating more physicians, many of whom will practice in the region, said Michael E. Cain, MD, vice president for health sciences at UB and dean of the medical school. It allows UB to hire more talented faculty, bringing to this community much-needed clinical services and medical training programs.

HOKs design for UBs medical school creates the heart for the new Buffalo Niagara Medical Campus while integrating and connecting to the surrounding communities," said Kenneth Drucker, FAIA, design principal for the project and design director for HOKs New York office. "The buildings atrium will be the focal point for bringing together clinical, basic sciences and educational uses fostering collaboration.

The buildings first two floors will house multipurpose educational and community spaces for medical school and community outreach programs.

A second-floor bridge will link to the new John R. Oishei Childrens Hospital and the Conventus medical office building under construction along High Street adjacent to UBs new medical school.

See more here:

University at Buffalo Unveils HOK Design for Downtown Medical School

LIBERTY MUTUAL VERIFICATION HOSPITAL SENT RECORDS SENT TO DR TALEGHANI M2U01737 – Video


LIBERTY MUTUAL VERIFICATION HOSPITAL SENT RECORDS SENT TO DR TALEGHANI M2U01737
DID NOT MISUNDERSTAND, I JUST FORGOT. I WAS TO PICK UP COPIES FOR #39; MYSELF #39; ON THE LAST VISITS. UPS TRACKING NUMBERS TO BOTH SETS OF RECORDS SENT TO BOTH OF...

By: WheepingWillow2

Excerpt from:

LIBERTY MUTUAL VERIFICATION HOSPITAL SENT RECORDS SENT TO DR TALEGHANI M2U01737 - Video